Skip to content

Why the $300 generic EpiPen will just extend Mylan's profitability

perfectprice.io
10 pointsthegeneralist2 comments
On HN

Comments

Good writeup about dynamic pricing.

I see analogues to some store-brand items that are in fact made by a big brand using its excess production capacity, or a family of brands that has similar-but-distinct products at different price points.

True, though a key difference is retailers (Walmart especially) aggressively negotiate against manufacturers to lower prices. For high end manufactured brands sold in retail, like soap, trash bags, etc., store brands are created by competing manufacturers in part to add negotiating leverage against a P&G or other major manufacturer. And there are few CPG categories without significant competition.

With pharmaceuticals, production capacity is hardly an issue. It will, ironically, cost Mylan more to make the "generic" new brand (pay for new branding, packaging, etc.) than it will to make and package the existing brand.

AboutSource Built by g1lg1l

Hackerly is an independent reader for Hacker News, built on the public HN API. Not affiliated with Y Combinator.